Invitae is facing two main challenges - assembling a coherent business model from dozens of acquisitions and avoiding a cash crunch looming in 2024/2025. The company has taken decisive action to ...

Late Friday, the U.S. FDA granted De Novo marketing authorization for the Invitae Common Hereditary Cancers Panel. The panel is the first of its kind to receive FDA marketing authorization. Invitae is ...

Invitae (NYSE: NVTA) is a genetic testing company that's in its early growth stages, so shareholders should expect to take on some risk with a stock like this. But in Invitae's case, the company is ...

SAN FRANCISCO--(BUSINESS WIRE)--Invitae Corporation (NYSE:NVTA), a genetic information company, today announced that it has expanded its genetic testing offering with hundreds of additional genes and ...

Shares of the genetic testing company have more than doubled in less than a week. It likely isn’t durable. It was also truly bizarre. Invitae announced a strategic pivot and provided financial ...